<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895268</url>
  </required_header>
  <id_info>
    <org_study_id>PEP02-03</org_study_id>
    <nct_id>NCT03895268</nct_id>
  </id_info>
  <brief_title>Influenza A+B Test Kit Performance Study</brief_title>
  <official_title>Prospective In Vitro Diagnostic Clinical Performance Study for an Influenza A+B Point-of-Care Test Kit on Patients Exhibiting Influenza-like Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanwa BioTech Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prince of Wales Hospital, Shatin, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanwa BioTech Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective clinical study on the performance of an Influenza A+B rapid test kit. The main&#xD;
      goal is to establish the sensitivity and specificity (i.e. how accurate the test is) when&#xD;
      compared to a gold standard.&#xD;
&#xD;
      Option of participating in this clinical study will be presented to patients displaying&#xD;
      influenza-like illness. Informed consent will be collected from patients or patient's next of&#xD;
      kin/guardian before samples (nasopharyngeal swab) are taken from the patient.&#xD;
&#xD;
      Nasopharyngeal swabs are tested using both the investigational test kit and a predicate&#xD;
      fluorescence immunoassay test kit. All samples will be tested using a molecular-based PCR&#xD;
      test kit as a confirmatory test.&#xD;
&#xD;
      The results will be analysed statistically and the performance of the Influenza A+B test kit&#xD;
      can be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Influenza is an acute respiratory infection caused by influenza viruses which circulate in&#xD;
      all parts of the world. Influenza viruses are causative agents of highly contagious, acute,&#xD;
      viral infections of the respiratory tract. Influenza viruses are immunologically diverse,&#xD;
      single-stranded RNA viruses.&#xD;
&#xD;
      There are 3 types of seasonal influenza viruses, types A, B, and C. Influenza A+B and B&#xD;
      viruses circulate and cause outbreaks and epidemics. Influenza type C virus is detected much&#xD;
      less frequently and usually causes mild infections, thus presents less significant public&#xD;
      health implications.&#xD;
&#xD;
      Seasonal influenza has an incubation period of approximately 2 days and is characterized by a&#xD;
      sudden onset of fever, cough, headache, muscle and joint pain, severe malaise, sore throat&#xD;
      and a runny nose. Most people recover within a week without requiring medical attention but&#xD;
      influenza can cause severe illness or death especially in vulnerable populations such as&#xD;
      children, pregnant women and elderlies. Seasonal influenza causes public health concerns as&#xD;
      it spreads easily, with rapid transmission in crowded areas including schools and nursing&#xD;
      homes.&#xD;
&#xD;
      Antiviral drugs for Influenza A and Influenza B are available in some countries and may&#xD;
      reduce severe complications and deaths. Ideally these antiviral drugs need to be administered&#xD;
      within 48 hours of onset of symptoms and hence rapid diagnosis of influenza in patients&#xD;
      displaying influenza-like Illness can reduce the number of severe complications and deaths&#xD;
      associated with influenza.&#xD;
&#xD;
      Fluorescent Immunoassay is a biochemical technique used for detecting the binding of the&#xD;
      &quot;detection&quot; antibody and the analyte molecule. The advantages of a fluorescent detection&#xD;
      system have been known for many years. These include higher sensitivity detection of the&#xD;
      analyte, simplified reagents and simpler assay designs. Several breakthroughs have occurred&#xD;
      over the past few years that have enabled the implementation of a fluorescent based&#xD;
      immunoassay system at the point of care.&#xD;
&#xD;
      A modern fluorescent based immunoassay uses a fluorescent compound, which absorbs light or&#xD;
      energy (excitation energy) at a specific wavelength and then emits light or energy at a&#xD;
      different wavelength, as the detection reagent. The difference between the wavelength of the&#xD;
      excitation light and the emission light is called the Stokes shift. The greater the shift or&#xD;
      difference in the wavelength the less interference there will be by having the excitation&#xD;
      light detected as part of the emission light. Recently many technical improvements have&#xD;
      occurred that has enabled the implementation of a high sensitivity immunoassay system. These&#xD;
      include the availability of narrow wavelength low cost light sources, newer more stable&#xD;
      fluorophores that have very wide Stokes shifts, stable solid state light detectors and&#xD;
      microprocessors to process and analyse the data from each test.&#xD;
&#xD;
      When a fluorescent detection system is linked to a lateral flow assay and matched with a&#xD;
      powerful analyser like the ALiA Diagnostic Platform, the result is improved assay&#xD;
      performance, the opportunity for walk away testing along with the elimination of&#xD;
      misinterpretation often associated with visually-read point-of-care assays.&#xD;
&#xD;
      Influenza A and Influenza B affect all population, any patients of age 18 or above displaying&#xD;
      symptoms of respiratory infection will be included as potential participants.&#xD;
&#xD;
      There will be no restriction on the ethnicity of patients but the majority of patients to be&#xD;
      recruited are expected to be of Asian origin as the clinical trial is based in Hong Kong.&#xD;
      However, it has been proved that Influenza strains do not vary / have minimal variation in&#xD;
      human of different ethnicity.&#xD;
&#xD;
      Study Design:&#xD;
&#xD;
      Option for participating in this clinical study will be presented to patients satisfying the&#xD;
      patient selection criteria. Informed consent will be collected from patients before samples&#xD;
      (nasopharyngeal swab) are taken.&#xD;
&#xD;
      Nasopharyngeal swabs are tested using the investigational products, a predicate fluorescence&#xD;
      immunoassay test, and a molecular-based PCR test will be used as the gold standard.&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      Considering the seasonal nature of the disease, duration of the study is estimated to be&#xD;
      approximately 24 months from inclusion of first subject to the day of final analysis of the&#xD;
      last subject's sample.&#xD;
&#xD;
      Study Hypothesis:&#xD;
&#xD;
      When compared to PCR:&#xD;
&#xD;
      The positive percent agreement (sensitivity) for the investigational product when testing for&#xD;
      influenza A and influenza B should be at least 85 percent with a lower bound of the 95&#xD;
      percent confidence interval that is greater than or equal to 70 percent.&#xD;
&#xD;
      The negative percent agreement (specificity) for the Investigational Product when testing for&#xD;
      influenza A is at least 90 percent with a lower bound of the 95 percent confidence interval&#xD;
      that is greater than or equal to 80 percent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2022</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The clinical sensitivity and clinical specificity of the investigational devices</measure>
    <time_frame>2 Years</time_frame>
    <description>Establish clinical sensitivity and specificity of investigational devices by comparing with PCR results using fresh and frozen sample</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Influenza Type A</condition>
  <condition>Influenza Type B</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALiA Analyser</intervention_name>
    <description>NPS specimens shall be tested with the investigational device</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Influenza A+B Test Kit</intervention_name>
    <description>NPS specimens shall be tested with the investigational device</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The study will use nasopharyngeal swab specimens taken from hospitalized subjects displaying&#xD;
      influenza-like illness.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Influenza A and Influenza B affect all population, any patients of age 18 or above&#xD;
        displaying symptoms of respiratory infection will be included as potential participants.&#xD;
&#xD;
        There will be no restriction on the ethnicity of patients but the majority of patients to&#xD;
        be recruited are expected to be of Asian origin as the clinical trial is based in Hong&#xD;
        Kong. However, it has been proved that Influenza strains do not vary / have minimal&#xD;
        variation in human of different ethnicity.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is having NPA collected by the hospital as routine testing&#xD;
&#xD;
          -  Patient or patient's next of kin/guardian is willing and able to give informed consent&#xD;
             for participation in the trial.&#xD;
&#xD;
          -  Patients presented with influenza-like illness, i.e. fever and cough, with onset of&#xD;
             illness within 7 days of hospital admission&#xD;
&#xD;
          -  Male or Female, 18 years of age or above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ Have had influenza-specific treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul KS Chan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Veronica Wong, Dr.</last_name>
    <phone>+852 2698 7970</phone>
    <email>veronica@sanwabiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

